Published March 24, 2022 / All Stories
Sequencing the first human genome was considered one of the greatest feats in science and medicine. Twenty years later, scientists have now sequenced the most complete human genome yet. Although we have the blueprint for what makes us human, interpreting it is another challenge. The scientific community has yet to fully unlock the knowledge within it to help answer our current - and future - questions about disease.
With access to more than one million genomes, AbbVie is leading one of the largest genomics research efforts in the field. It’s a lot of DNA data to unlock, but scientists at AbbVie’s Genomics Research Center aren’t intimidated by that.
How the field of genomics helps us discover and develop medicines faster
Almost all small molecule drugs and biotherapeutics work by disturbing the function of proteins. Drug development is centered around identifying proteins, or targets, that play a causal role in disease. And since DNA contains the information needed to make proteins in our bodies, genetics and genomics play an important role in developing medicines for patients.
It’s an exciting time for genomics research right now. With new advances in technology, scientists can do things that wouldn’t have been possible just a few years ago, like sequencing the previously indecipherable sequences of the human genome.
With access to massive data sets from large population cohorts, real-world data, whole-genome sequencing, single-cell transcriptomics, epigenetics and more, AbbVie is building a greater understanding of disease biology and how medicine works at the individual level. Using genetics and genomics, the company believes it can disrupt the drug discovery and development paradigm by reducing failure rates and accelerating the development of medicines for patients.